Novel Progress in Cancer Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 325
Special Issue Editor
Interests: exosomes; immunotherapy; bladder cancer; lung cancer; breast cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy revolutioned the cancer treatment landscape with advancing developments in oncoimmunology. However, only a low percentage of patients clinically benefit from immune therapeutic agents. Therefore, there is an urgent need to understand the signaling pathways that regulate the cross-talk between tumor cells and immune cells and the relevant treatment-driven resistance mechanisms. Dissecting these dynamic interactions will allow us to discover new targetable molecules in order to develop therapeutic agents or combination therapies to enhance the anti-tumor immune response. In addition, the identification of novel predictive and prognostic immune biomarkers of cancer progression and immunotherapy response will improve the patients’outcome.
The Special Issue “Novel Progress in Cancer Immunotherapy” welcomes research articles and reviews including in vitro and in vivo studies on immune checkpoint inhibitors, anti-cancer vaccines, antibody-based therapies and adoptive cell therapies to widely explore the rapidly moving field of immunotherapy.
Dr. Sheila Spada
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint blockers
- CAR-T
- solid tumor
- liquid tumor
- cancer therapy
- immunology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
